Museum Centre Vapriikki: Ancient DNA Reveals 800-year-old Family Link in Medieval Finland
Ancient DNA research led by the Museum Centre Vapriikki in Tampere, Finland, in collaboration with the universities of Turku and Helsinki, has produced new insights into kinship, health, and population continuity in medieval and early modern Finland. Published in the peer-reviewed journal iScience, the research presents results from 25 individuals in Finland – a significant result in a country where acidic soils often lead to poor preservation of bones and genetic material.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807066724/en/
The woman’s grave in Vilusenharju, Tampere was discovered in 1962, and the man’s grave in Ristiänmäki, Pälkäne in 1982. Ancient DNA research has now revealed that the deceased were siblings. Illustrations by Veronika Paschenko. Photo by Vapriikki.
Researchers successfully recovered DNA from individuals buried between the 12th and 19th centuries at three cemeteries in the Tampere region. The study is part of Vapriikki’s research project that applies scientific methods to investigate the region’s past.
Family ties and genetic continuity
One of the study’s findings was the discovery of full siblings buried 30 kilometers apart. A woman buried in Tampere and a man in Pälkäne, both from the 12th century, were confirmed to be sister and brother.
“This provides tangible evidence of family connections between different communities,” says Dr. Ulla Nordfors, researcher at Vapriikki.
Comparisons with over 4,000 modern Finnish genomes from the Finnish Institute for Health and Welfare’s biobank revealed that the ancient individuals from Tampere region share the closest genetic affinities with people living in the same region today.
“These results point to a remarkable degree of genetic continuity in the area since at least the early Middle Ages,” says Sanni Peltola, a doctoral researcher at the University of Helsinki.
Additional genetic links were detected between Finnish individuals and previously published ancient genomes from Scandinavia and the Lake Ladoga region, providing evidence of mobility and cultural contacts in the Viking Age and beyond.
“Although the dataset is relatively small, the findings clearly show that medieval Finland was not isolated,” Peltola notes. “It was part of the wider networks of interaction that shaped northern Europe.”
Health and traits revealed
The analysis also recovered microbial DNA that sheds light on health in past populations. Bacteria in 13th-century dental calculus included species linked to both oral and systemic health. DNA from a post-medieval man revealed the presence of Treponema, a bacterial genus that includes the causative agent of syphilis.
Hereditary traits were also uncovered. Most individuals were lactose tolerant, like modern Finns, and a 12th-century man likely had corneal dystrophy, a degenerative eye disease that may have impaired his vision.
“Genes cannot capture the full complexity of a person and their life, but learning about health, traits, and family ties can help us see ancient people as individuals who once lived, felt, and experienced the world,” says Nordfors. “When interpreted within their archaeological and historical context, these details allow us to approach the past on a more human level.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807066724/en/
Contacts
Ulla Nordfors, ulla.nordfors@tampere.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven1.9.2025 09:49:00 EEST | Press release
CapVest Partners LLP (“CapVest”), a leading global investment firm, has today signed a definitive agreement with Bain Capital and Cinven to acquire the majority stake in STADA Arzneimittel AG “(STADA” or “the Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals. Headquartered in Bad Vilbel, Germany, STADA is a leading European pharmaceutical company focused on three strategic pillars: Consumer Healthcare, Generics and Specialty Pharmaceuticals. The company was acquired by Bain Capital and Cinven in 2017. Working with management, the two international investment firms helped transform the company from a traditional German generics business into a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. During this period, STADA grew into a multifaceted, resilient company, generating revenues in excess of €4 billion, delivering a
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom